Vaccinex (VCNX) Competitors $1.21 +0.20 (+19.80%) (As of 12/20/2024 05:32 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VCNX vs. LUMO, MRKR, CALC, TPST, BRNS, AFMD, OKYO, ANEB, VRCA, and OTLKShould you be buying Vaccinex stock or one of its competitors? The main competitors of Vaccinex include Lumos Pharma (LUMO), Marker Therapeutics (MRKR), CalciMedica (CALC), Tempest Therapeutics (TPST), Barinthus Biotherapeutics (BRNS), Affimed (AFMD), OKYO Pharma (OKYO), Anebulo Pharmaceuticals (ANEB), Verrica Pharmaceuticals (VRCA), and Outlook Therapeutics (OTLK). These companies are all part of the "pharmaceutical products" industry. Vaccinex vs. Lumos Pharma Marker Therapeutics CalciMedica Tempest Therapeutics Barinthus Biotherapeutics Affimed OKYO Pharma Anebulo Pharmaceuticals Verrica Pharmaceuticals Outlook Therapeutics Lumos Pharma (NASDAQ:LUMO) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Do analysts recommend LUMO or VCNX? Lumos Pharma presently has a consensus target price of $8.63, indicating a potential upside of 98.73%. Given Lumos Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Lumos Pharma is more favorable than Vaccinex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lumos Pharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders hold more shares of LUMO or VCNX? 34.0% of Lumos Pharma shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 25.4% of Lumos Pharma shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, LUMO or VCNX? Lumos Pharma has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Vaccinex has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Does the MarketBeat Community favor LUMO or VCNX? Vaccinex received 86 more outperform votes than Lumos Pharma when rated by MarketBeat users. However, 75.51% of users gave Lumos Pharma an outperform vote while only 60.00% of users gave Vaccinex an outperform vote. CompanyUnderperformOutperformLumos PharmaOutperform Votes3775.51% Underperform Votes1224.49% VaccinexOutperform Votes12360.00% Underperform Votes8240.00% Does the media favor LUMO or VCNX? In the previous week, Vaccinex had 6 more articles in the media than Lumos Pharma. MarketBeat recorded 6 mentions for Vaccinex and 0 mentions for Lumos Pharma. Lumos Pharma's average media sentiment score of 0.00 beat Vaccinex's score of -0.28 indicating that Lumos Pharma is being referred to more favorably in the media. Company Overall Sentiment Lumos Pharma Neutral Vaccinex Neutral Is LUMO or VCNX more profitable? Vaccinex has a net margin of 0.00% compared to Lumos Pharma's net margin of -1,583.49%. Vaccinex's return on equity of 0.00% beat Lumos Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lumos Pharma-1,583.49% -233.03% -129.88% Vaccinex N/A N/A -383.58% Which has stronger valuation & earnings, LUMO or VCNX? Vaccinex has lower revenue, but higher earnings than Lumos Pharma. Lumos Pharma is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLumos Pharma$2.21M17.02-$34.03M-$4.29-1.01Vaccinex$388K8.11-$20.25M-$48.27-0.03 SummaryLumos Pharma beats Vaccinex on 10 of the 19 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Vaccinex News Delivered to You Automatically Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCNX vs. The Competition Export to ExcelMetricVaccinexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.76M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.0310.5990.1317.19Price / Sales8.11196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book-0.475.094.784.78Net Income-$20.25M$151.83M$120.31M$225.60M7 Day Performance-67.21%-2.14%-1.92%-1.23%1 Month Performance-66.57%-4.56%13.65%0.46%1 Year Performance-87.69%8.87%28.34%15.24% Vaccinex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCNXVaccinex0.9772 of 5 stars$1.21+19.8%N/A-85.7%$2.76M$388,000.00-0.0340Gap UpLUMOLumos Pharma3.0986 of 5 stars$4.34flat$8.63+98.7%+45.6%$37.54M$2.21M-1.0130High Trading VolumeMRKRMarker Therapeutics4.0507 of 5 stars$4.19+2.9%$19.00+353.5%-4.8%$37.38M$3.31M0.0060News CoveragePositive NewsCALCCalciMedica2.9484 of 5 stars$2.76+1.1%$19.33+600.5%-7.1%$37.21MN/A-2.5330Positive NewsTPSTTempest Therapeutics1.8299 of 5 stars$0.84+5.0%$20.00+2,281.0%-80.8%$36.66MN/A0.0020BRNSBarinthus Biotherapeutics1.5315 of 5 stars$0.90-1.4%$5.83+548.1%-66.8%$36.21M$800,000.00-0.61107Gap UpAFMDAffimed4.4536 of 5 stars$2.15flat$13.50+527.9%-73.8%$34.62M$8.95M0.0076Analyst RevisionNews CoverageOKYOOKYO Pharma1.5557 of 5 stars$1.02-3.8%$7.00+586.3%-38.4%$34.52MN/A0.007ANEBAnebulo Pharmaceuticals1.9538 of 5 stars$1.30-7.1%$8.00+515.4%-60.7%$33.71MN/A-4.674News CoverageGap UpVRCAVerrica Pharmaceuticals4.6589 of 5 stars$0.74-3.1%$9.50+1,188.7%-89.2%$33.62M$5.12M-0.4240Analyst ForecastNews CoverageOTLKOutlook Therapeutics1.8305 of 5 stars$1.42-4.1%$42.34+2,881.9%-83.2%$33.60MN/A0.0020 Related Companies and Tools Related Companies LUMO Competitors MRKR Competitors CALC Competitors TPST Competitors BRNS Competitors AFMD Competitors OKYO Competitors ANEB Competitors VRCA Competitors OTLK Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VCNX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
